Litcius/Paper detail

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Sibylle Loibl, Andreas Schneeweiß, Jens Huober, Michael Braun, Julia Rey, Jens‐Uwe Blohmer, Jenny Furlanetto, D M Zahm, Claus Hanusch, Jörg Thomalla, Christian Jackisch, Peter Staib, Theresa Link, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Valentina Nekljudova, Carsten Denkert, Michael Untch

2022Annals of Oncology244 citationsDOI

Topics & Concepts

MedicineDurvalumabHazard ratioBreast cancerInternal medicineOncologyPlaceboEpirubicinConfidence intervalCyclophosphamideCancerChemotherapyPathologyImmunotherapyNivolumabAlternative medicineBreast Cancer Treatment StudiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response | Litcius